Iranian Researchers Produce Drug to Treat Lymphoma Cancer
“In recent years, Ibrutinib tablets have been introduced as an alternative to unsuccessful treatment for patients with lymphoma, and this type of treatment is also used inside Iran,” said Sahar Bahmani, the managing director of the knowledge-based company.
“Since the medication was in Iran’s pharmaceutical portfolio as a single prescription and with high costs, our company started research to produce it in the country years ago, and produced Ibrutinib tablet after years of research,” she added.
Bahmani explained that the pill causes destruction and removal of cancer cells in the patient's body, adding that the drug has been marketed under the brand names of Broca 140 and Broca 420 and will meet the country’s needs.
Also, in September, researchers at an Iranian nanotechnology company succeeded in finding the formulation for production of nanoliposomal doxorubicin used for the treatment of cancer patients.
Ketabi, the marketing manager of Exir Nano Sina company, underlined the therapeutic effects of nanoliposomal doxorubicin in cancer treatment and the role of nanocurcumin in COVID-19 produced by the company.
He also referred to the production of first injectable anti-cancer nanomedicine product in the country with the scientific participation of Mashhad Faculty of Pharmacy, saying that these products are mainly made by lipid-based formulations in two forms of liposomal and nanomicelle.
Ketabi noted that using nanotechnology in these products increases their effectiveness and decreases their toxicity compared to other samples.
4155/v
